Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system. Although it has been extensively studied, the proximate trigger of the immune response remains uncertain. Experimental autoimmune encephalomyelitis in the common marmoset recapitulates many radiological and pathological features of focal multiple sclerosis lesions in the cerebral white matter, unlike traditional experimental autoimmune encephalomyelitis in rodents. This provides an opportunity to investigate how lesions form as well as the relative timing of factors involved in lesion pathogenesis, especially during early stages of the disease. We used MRI to track experimental autoimmune encephalomyelitis lesions in vivo to determine their age, stage of development, and location, and we assessed the corresponding histopathology post-mortem. We focused on the plasma protein fibrinogen-a marker for blood-brain barrier leakage that has also been linked to a pathogenic role in inflammatory demyelinating lesion development. We show that fibrinogen has a specific spatiotemporal deposition pattern, apparently deriving from the central vein in early experimental autoimmune encephalomyelitis lesions <6 weeks old, and preceding both demyelination and visible gadolinium enhancement on MRI. Thus, fibrinogen leakage is one of the earliest detectable events in lesion pathogenesis. In slightly older lesions, fibrinogen is found inside microglia/macrophages, suggesting rapid phagocytosis. Quantification demonstrates positive correlation of fibrinogen deposition with accumulation of inflammatory cells, including microglia/macrophages and T cells. The peak of fibrinogen deposition coincides with the onset of demyelination and axonal loss. In samples from chronic multiple sclerosis cases, fibrinogen was found at the edge of chronic active lesions, which have ongoing demyelination and inflammation, but not in inactive lesions, suggesting that fibrinogen may play a role in sustained inflammation even in the chronic setting. In summary, our data support the notion that fibrinogen is a key player in the early pathogenesis, as well as sustained inflammation, of inflammatory demyelinating lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Self-citationImmunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
New tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
An updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692 · cited 2×
“We also looked for fibrinogen deposition in both chronic active and chronic inactive multiple sclerosis lesions (Lassmann et al., 1998; Kuhlmann et al., 2017).”
BackgroundKERMODE, A. G., THOMPSON, A. J., TOFTS, P., MACMANUS, D. G., KENDALL, B. E., KINGSLEY, D. P. E., MOSELEY, I. F., RUDGE, P., & MCDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.5.1477 · Cited by 578
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
TMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434
Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
Kirk, J., Plumb, J., Mirakhur, M., & McQuaid, S. (2003) · The Journal of Pathology · doi:10.1002/path.1434 · Cited by 375 · cited 1×
“immunoglobulins, as well as other molecules involved in the neurovascular unit that governs the brain’s permeability to such plasma proteins and may affect the inflammatory demyelinating processes (Kirk et al., 2003; Bennett et al., 2010), would be an important next step for validating the specificity of fibrinogen’s…”
BackgroundAdams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061931 · Cited by 335
Self-citationDisruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334
Ryu, J. K., Petersen, M. A., Murray, S. G., Baeten, K. M., Meyer-Franke, A., Chan, J. P., Vagena, E., Bedard, C., Machado, M. R., Coronado, P. E. R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9164 · Cited by 271 · cited 20×
“As fibrinogen has been investigated to be necessary and sufficient for early pathogenesis of inflammatory demyelination in rodents (Davalos et al., 2012; Ryu et al., 2015) but not in non-human primates, we investigated the spatiotemporal dynamics of fibrinogen deposition in marmoset EAE by creating a radiology-to-path…”
BackgroundInfluentialSelf-citationHAWKINS, C. P., MUNRO, P. M. G., MACKENZIE, F., KESSELRING, J., TOFTS, P. S., BOULAY, E. P. G. H. D., LANDON, D. N., & McDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.2.365 · Cited by 219
Tomimoto, H., Akiguchi, I., Suenaga, T., Nishimura, M., Wakita, H., Nakamura, S., & Kimura, J. (1996) · Stroke · doi:10.1161/01.str.27.11.2069 · Cited by 204 · cited 2×
“There are other diseases of the CNS with blood–brain barrier abnormalities and fibrin deposition, such as stroke and Alzheimer’s Disease (Tomimoto et al., 1996; Sandoval and Witt, 2008; Erickson and Banks, 2013; Cortes-Canteli et al., 2015; Kassner and Merali, 2015), that do not harbour the same phenotype and pathophy…”
BackgroundVos, C. M. P., Geurts, J. J. G., Montagne, L., van Haastert, E. S., Bö, L., van der Valk, P., Barkhof, F., & de Vries, H. E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.06.012 · Cited by 188 · cited 1×
“nohistochemical marker for blood–brain barrier leakage, but interestingly it has also been identified as having a pathogenic role in neurodegenerative diseases (Gay and Esiri, 1991; Claudio et al., 1995; Vos et al., 2005; Marik et al., 2007; Cortes-Canteli et al., 2012) and in multiple sclerosis lesion development (Ry…”
BackgroundEvolution of the blood–brain barrier in newly forming multiple sclerosis lesions
Gaitán, M. I., Shea, C. D., Evangelou, I. E., Stone, R. D., Fenton, K. M., Bielekova, B., Massacesi, L., & Reich, D. S. (2011) · Annals of Neurology · doi:10.1002/ana.22472 · Cited by 174 · cited 1×
“blood–brain barrier disruption is a dynamic process throughout lesion formation (Gaitán et al., 2011).”
BackgroundSelf-citationDysferlin Is a New Marker for Leaky Brain Blood Vessels in Multiple Sclerosis
Hochmeister, S., Grundtner, R., Bauer, J., Engelhardt, B., Lyck, R., Gordon, G., Korosec, T., Kutzelnigg, A., Berger, J. J., Bradl, M., et al. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235119.52311.16 · Cited by 160
Alvarez, J. I., Saint-Laurent, O., Godschalk, A., Terouz, S., Briels, C., Larouche, S., Bourbonnière, L., Larochelle, C., & Prat, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.09.016 · Cited by 150
Leech, S., Kirk, J., Plumb, J., & McQuaid, S. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00781.x · Cited by 137
The formation of inflammatory demyelinated lesions in cerebral white matter
Maggi, P., Macri, S. M. C., Gaitán, M. I., Leibovitch, E., Wholer, J. E., Knight, H. L., Ellis, M., Wu, T., Silva, A. C., Massacesi, L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24242 · Cited by 110 · cited 3×
“To investigate the role of fibrinogen in the pathogenesis of inflammatory demyelinating lesions, we first used serial in vivo proton density-weighted MRI to date the appearance of focal lesions in the white matter (Maggi et al., 2014).”
BackgroundMethodResultInfluentialSelf-citationAlbumin and multiple sclerosis
LeVine, S. M. (2016) · BMC Neurology · doi:10.1186/s12883-016-0564-9 · Cited by 105
Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface
Bardehle, S., Rafalski, V. A., & Akassoglou, K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00354 · Cited by 76
Self-citation
Cited by
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.004 · Cited by 440
Self-citationFibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
Ryu, J. K., Rafalski, V. A., Meyer-Franke, A., Adams, R. A., Poda, S. B., Rios Coronado, P. E., Pedersen, L. Ø., Menon, V., Baeten, K. M., Sikorski, S. L., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0232-x · Cited by 213
Mechanisms underlying progression in multiple sclerosis
Absinta, M., Lassmann, H., & Trapp, B. D. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000818 · Cited by 175
“Although the inflammatory process in progressive multiple sclerosis is not associated with overt blood–brain barrier damage, there is a moderate permeability increase in chronic active [40] as well”
BackgroundSelf-citationChronic inflammation in multiple sclerosis - seeing what was always there
Matthews, P. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0240-y · Cited by 128
Metadata
- Authors
- Lee, N. J., Ha, S.-K., Sati, P., Absinta, M., Luciano, N. J., Lefeuvre, J. A., Schindler, M. K., Leibovitch, E. C., Ryu, J. K., Petersen, M. A., Silva, A. C., Jacobson, S., Akassoglou, K., & Reich, D. S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-20
- Volume
- 141
- Issue
- 6
- Pages
- 1637-1649
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2802867173
- Cited by
- 65
- References
- 23
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.